Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 1, 2001, Pages 87-103

  Hirschowitz, B I ^a   Haber, M M ^b  

^a University of Alabama at Birmingham   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; ENTEROCHROMAFFIN CELL; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ENTEROCHROMAFFIN-LIKE CELLS; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRINS; GASTRITIS; HELICOBACTER PYLORI; HUMANS; HYPERPLASIA; INTESTINAL MUCOSA; MALE; METAPLASIA; MIDDLE AGED; OMEPRAZOLE; ZOLLINGER-ELLISON SYNDROME;

EID: 0035176549     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00876.x     Document Type: Article

References (48)

1. Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection
2. Prevalence of peptic ulcer in Helicobacter pylori positive blood donors
3. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
4. Helicobacter pylori
5. In a world of black and white, Helicobacter pylori is gray
6. Risk factors associated with refractory peptic ulcers
7. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer
8. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding
9. Evidence of aspirin use in both upper and lower gastrointestinal perforation
10. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h
11. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome
12. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy
13. Helicobacter pylori and Zollinger-Ellison syndrome
14. Clinical course of nonsurgically treated Zollinger-Ellison syndrome
15. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
16. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety
17. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
18. Lack of effect of acid suppression therapy on gastric atrophy
19. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls
20. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion
21. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls
22. Histological classification of gastritis and Helicobacter pylori infection: An agreement at last? The International Workshop on the Histopathology of Gastritis
23. Rapid metallic histologic staining using the microwave oven
24. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients
25. Histopathological classification of nonantral gastric endocrine growths in man
26. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole
27. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients
28. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: A morphological approach to the study of ulcerogenesis in man
29. Helicobacter pylori and hypergastrinemia during proton pump inhibitor therapy
30. Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion
31. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment
32. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
33. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients
34. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment
35. Argyrophil-cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease
36. Gastritis, Helicobacter pylori, and proton pump inhibitors
37. Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients
38. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole
39. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastrooesophageal reflux disease
40. Changes in the gastric mucosa following eradication of Helicobacter pylori
41. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions and carcinoids arising in chronic atrophic gastritis
42. Gastrin is the most important factor in ECL tumorigenesis
43. Reply: Gastrin is the most important factor in ECL tumorigenesis
44. Clinical aspects of ECL cell abnormalities. Presented at Symposium on 'the Biological and Clinical Relevance of the Gastric Enterochromaffin-Like (ECL) Cell'
45. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases
46. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type i multiple endocrine neoplasia. A newly recognized association
47. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells